The first diagnostic test to classify cancers by differences in microRNAs–small pieces of RNA that regulate genes–will soon be on the market. The test distinguishes two types of lung cancer and should help doctors tailor treatments to their patients’ needs. Scientists say that tests based on microRNA profiles could prove more sensitive and reliable than existing methods, whose accuracy depends heavily on the judgment of the people analyzing them.
Product: MicroRNA test for lung cancer
Cost: Comparable to that of other molecular tests for cancer, which are priced at around $3,000 to $3,500
Company: Rosetta Genomics
Subscribe to Continue Reading
Uh oh–you've read all five of your free articles for this month.
Insider Online Only
$19.95/yr US PRICE
Freeze-Dried Molecules Can Be Used to Whip Up Medicines Anywhere
The approach could be a tenth the price of earlier methods.
It Costs $30 to Make a DIY EpiPen, and Here’s the Proof
The medical maker collective Four Thieves Vinegar made an “EpiPencil” for a tiny fraction of what the EpiPen manufacturer Mylan charges.
17 and Going Blind: The High Stakes of Getting into a Gene Therapy Trial
For patients with some inherited diseases, a chance to test an experimental treatment can offer the only hope.